3.13
-0.08 (-2.49%)
| Previous Close | 3.21 |
| Open | 3.17 |
| Volume | 2,417,696 |
| Avg. Volume (3M) | 2,750,048 |
| Market Cap | 627,154,944 |
| Price / Sales | 2.55 |
| Price / Book | 8.51 |
| 52 Weeks Range | |
| Earnings Date | 30 Jul 2026 |
| Profit Margin | -10.23% |
| Operating Margin (TTM) | -13.54% |
| Diluted EPS (TTM) | -0.100 |
| Quarterly Revenue Growth (YOY) | 12.70% |
| Total Debt/Equity (MRQ) | 176.82% |
| Current Ratio (MRQ) | 2.32 |
| Operating Cash Flow (TTM) | 8.56 M |
| Levered Free Cash Flow (TTM) | 7.81 M |
| Return on Assets (TTM) | -3.82% |
| Return on Equity (TTM) | -35.69% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | Cerus Corporation | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.5 |
| Average | -0.67 |
|
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety, and generates revenue from the same. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Core |
| % Held by Insiders | 3.35% |
| % Held by Institutions | 76.13% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |